Sign in

    Chris Marai

    Managing Director and Senior Equity Analyst at Nomura Instinet

    Chris Marai, Ph.D., is a Managing Director and Senior Equity Analyst at Nomura Instinet, specializing in biotechnology and healthcare research. He covers a range of companies including BeyondSpring, Sarepta Therapeutics, Syndax Pharmaceuticals, and Prothena Corporation, with a track record that includes a 51.61% success rate and an average return of 10.77% based on 33 ratings, ranking him #2,370 out of 4,884 analysts. Marai began his analyst career at Oppenheimer & Co. before joining Nomura Instinet as a Managing Director in 2016, bringing deep sector expertise in drug manufacturers and biotech innovation. He holds a Ph.D. and is FINRA-registered (CRD#: 5816694) with relevant securities licenses.

    Chris Marai's questions to Protagonist Therapeutics (PTGX) leadership

    Chris Marai's questions to Protagonist Therapeutics (PTGX) leadership • Q1 2020

    Question

    Chris Marai from Nomura Instinet asked for perspective on how PTG-300 would fit into daily clinical practice for polycythemia vera (PV), its potential placement in treatment lines relative to Jakafi, and any observed effects on spleen size.

    Answer

    Dr. Ronald Hoffman, Director of the Myeloproliferative Diseases Program at Mount Sinai, explained that PTG-300 could be a candidate for virtually all PV patients, both young and old. He sees it as an ideal treatment to avoid lifelong myelosuppressive therapy or as an adjunctive agent to eliminate the need for phlebotomies in patients on other treatments. Regarding spleen size, Dr. Hoffman noted that it's not a primary concern for most PV patients as they don't have symptomatic splenomegaly, and while animal models showed a reduction, the current human trial's sample size is too small to assess this endpoint.

    Ask Fintool Equity Research AI